Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...

Sarepta Therapeutics (SRPT) stock faces downgrades as it suspends 2025 revenue guidance amid safety concerns for its Duchenne gene therapy. Read more here.

Shares of Sarepta Therapeutics SRPT nosedived 35.9% on Friday following the death of a patient dosed with one of its ...

In May, Sarepta’s stock dropped further after it lowered its 2025 revenue guidance from $2.9 billion - $3.1 billion to $2.3 billion - $2.6 billion. This was attributed to ELEVIDYS.

What Happened? A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the ...

Analysts have recently evaluated Sarepta Therapeutics and provided 12-month price targets. The average target is $102.54, accompanied by a high estimate of $202.00 and a low estimate of $40.00. A ...

The Stock Declines as the Truth is Revealed On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure.

SRPT STOCK LOSS: Sarepta Therapeutics, Inc. Shareholders are Alerted of Ongoing Securities Fraud Investigation — Contact BFA Law (NASDAQ:SRPT) Provided by GlobeNewswire Jun 24, 2025, 12:18:00 PM ...

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector.

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential ...

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Sarepta Therapeutics, Inc. (NASDAQ: SRPT) for potential ...